Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B
Journal of Viral Hepatitis Dec 06, 2017
Nam JY, et al. - Researchers in this work investigated the development of hepatocellular carcinoma (HCC) or cirrhosis in hepatitis B e antigen (HBeAg) positive high viral load chronic hepatitis B (CHB) patients, according to the time needed to achieve complete viral suppression. They noticed that complete hepatitis B virus suppression within 2 years of antiviral therapy initiation had a correlation with the risk reduction of HCC or cirrhosis development.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
